Walleye Capital’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Walleye Capital’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,600	Closed	-$153K	–	6044
2023 Q4	$153K	Buy	+3,600	New	+$103K	﹤0.01%	3824
2023 Q2	–	Sell	-4,400	Closed	-$107K	–	5007
2023 Q1	$107K	Sell	4,400 -11,300	-72%	-$332K	﹤0.01%	2889
2022 Q4	$495K	Buy	+15,700	New	+$443K	0.01%	1458

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Walleye Capital's CERE Position: Q3 2024 in Review

Walleye Capital sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 40,000 shares — an estimated $1.64M sold.

Walleye Capital first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $1.69M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Walleye Capital reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Walleye Capital sold 40,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.64M.
Walleye Capital first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
Walleye Capital's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.69M in Q1 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.